Ser222
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser222  -  FANCD2 (human)

Site Information
LPEILGDsQHADVGK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447816

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 4 ) , mutation of modification site ( 3 , 4 ) , phospho-antibody ( 2 , 3 , 4 ) , western blotting ( 3 , 4 )
Disease tissue studied:
ataxia-telangiectasia ( 3 , 4 )
Relevant cell line - cell type - tissue:
AT22IJE-T (fibroblast) ( 4 ) , ATLD 6 (lymphoblastoid) ( 3 ) , FA-D2 (fibroblast) ( 2 , 3 , 4 ) , GM01526 (fibroblast) ( 4 ) , HeLa (cervical) ( 1 , 4 )

Upstream Regulation
Kinases, in vitro:
ATM (human) ( 4 )
Treatments:
ionizing_radiation ( 2 , 3 , 4 ) , mitomycin_C ( 3 )

Downstream Regulation
Effects of modification on biological processes:
cell cycle regulation ( 4 )

References 

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Ho GP, Margossian S, Taniguchi T, D'Andrea AD (2006) Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol 26, 7005-15
16943440   Curated Info

3

Nakanishi K, et al. (2002) Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol 4, 913-20
12447395   Curated Info

4

Taniguchi T, et al. (2002) Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109, 459-72
12086603   Curated Info